{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
alpha-tocopherol
to a specific field?
Status:
Investigational
Source:
NCT02207439: Phase 2 Interventional Completed Head and Neck Squamous Cell Carcinoma
(2014)
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Fluoromisonidazole (FMISO) is a small, water-soluble molecule with a molecular weight of 189.14 Daltons. It has an octanol:water partition coefficient of 0.41, so that it would be expected to reflect plasma flow as an inert, freely-diffusible tracer immediately after injection, but later images should reflect its tissue partition coefficient in normoxic tissues. Fluoromisonidazole is used as a positron emission tomography (PET) radiotracer for imaging hypoxia when labeled with fluorine-18. It is the most widely used nitroimidazole imaging agent for use as a non-invasive way to localize and quantify hypoxia.
Status:
Investigational
Source:
J Rheumatol. Oct 1996;23(10):1719-24.: Not Applicable Human clinical trial Completed Lupus Nephritis/metabolism
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT03599284: Phase 2 Interventional Completed Coronary Artery Disease
(2018)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT02445976: Phase 2 Interventional Completed Prostate Cancer
(2015)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Seviteronel (VT-464) is a 17,20-lyase selective inhibitor of CYP17A1, which plays key roles in adrenal and intratumoral de novo biosynthesis of androgens. The inhibition of 17,20-lyase activity by seviteronel (VT-464) is enough to reduce androgen levels, and its preserving of 17alpha-hydroxylase activity largely avoids interference with the production of other steroidal hormones. Seviteronel (VT-464) also has shown AR-antagonist activity independent of CYP17 enzyme inhibition. It is currently in phase 2 clinical trials as a therapeutic for castration-resistant prostate cancer patients.
Status:
Investigational
Source:
Clin Nephrol. Feb 1986;25(2):70-4.: Not Applicable Human clinical trial Completed Hyperlipidemias/complications
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
Pantetheine is the mercaptoethyl conjugated amide analog of pantothenic acid (Vitamin B5), an intermediate in the production of coenzyme A by the body. Pantetheine is part of two larger compounds (coenzyme A and acyl-carrier protein) that promote a large number of metabolic reactions essential for the growth and well-being of animals. Pantetheine has been found to ameliorate symptoms in various disease models but specifically in Pantothenate Kinase-Associated Neurodegeneration (PKAN). Pantetheine is usually administered in its disulfide form (i.e. pantethine) since pantethine is commercially available and is reduced to pantetheine in biological systems and pantethine was hydrolyzed to pantetheine and pantothenic acid prior to absorption. The applicability and efficacy of pantethine (therefore also pantetheine) as a clinical therapeutic however is hampered since both forms can be degraded by pantetheine present in the body.
Status:
Investigational
Source:
NCT01332695: Phase 2 Interventional Completed Essential Tremor
(2011)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
ST-101 (also known as ZSET1446) is an azaindolizinone derivative patented by Zenyaku Kogyo Kabushiki Kaisha for the treatment of Alzheimer's disease and improvement of cerebral function. In preclinical models, ST-101 stimulates acetylcholine release and improves methamphetamine-induced impairment of recognition memory in mice by activating extracellular signal-regulated kinase 1/2. Impaired neurogenesis observed in olfactory bulbectomized mice was significantly improved by chronic administration with ST-101. We confirmed that administration with mecamylamine, a nicotinic acetylcholine receptor antagonist, inhibits ST-101-enhanced neurogenesis in the dentate gyrus. ST-101 administration also restored decreased phosphorylation of Akt and extracellular signal-regulated kinase in the dentate gyrus of olfactory bulbectomized mice.
Status:
Investigational
Source:
NCT03406702: Phase 2 Interventional Completed Epilepsy
(2018)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Status:
Investigational
Source:
INN:lerimazoline [INN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Lerimazoline is a sympathomimetic drug that belongs to the imidazoline class of compounds, and is used as a nasal decongestant. Lerimazoline displayed high affinity for the 5-HT1A receptor and for the 5-HT1D receptor. Binding affinity estimates for α1-adrenoceptor, 5-HT2A, and D2 receptors were more than ten times lower. The mechanism of vasoconstrictor action of lerimazoline encompasses both, the activation of 5-HT2A, and to a lesser degree α1 -adrenergic receptors. These results also suggest that lerimazoline is an “atypical” decongestant. It inhibits secretion of nasal mucus. Lerimazoline causes hypertension.
Status:
Investigational
Source:
NCT02536781: Phase 2/Phase 3 Interventional Completed Inflammation of Mouth
(2015)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT02722018: Phase 1 Interventional Completed Healthy Volunteer
(2016)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
ARN-810 (GDC-0810) is a novel, orally bioavailable, estrogen receptor antagonist that induces proteasomal estrogen receptor degradation in breast cancer cell lines at picomolar concentrations and tumor regression in tamoxifen-sensitive and resistant BC xenograft models. Results from a first-in-human phase I/IIa study of ARN-810 indicate that it is tolerable and may benefit some postmenopausal women with advanced estrogen receptor-positive breast cancer. Development of ARN-810 was discontinued.
